Qinlock

Ripretinib

• Brand(s): Qinlock
• Dosage Form/Strength: 50 mg tablets
• Effective date: August 14, 2023

Initial criteria:

For the treatment of advanced gastrointestinal stromal tumour (GIST) in adult patients who meet ALL of the following criteria:

1. Aged 18 years old or older;
   AND
2. Has a confirmed diagnosis of metastatic and/or unresectable GIST;
   AND
3. Patient has experienced disease progression on, or intolerance (Note 1) to, imatinib, sunitinib, and regorafenib;
   AND
4. Has a good performance status;
   AND
5. Has adequate hematological and organ function;
   AND
6. Ripretinib is not being used in combination with other anticancer drugs for GIST;
   AND
7. Prescribed by a clinician experienced in the treatment of GIST.

Notes:

1. A detailed description of the experienced intolerance to each therapy must be provided with the application including the grade of toxicity where applicable. If a patient is deemed to have a contraindication to use one or more earlier lines of treatment, a description of the contraindication must be included with associated documentation and relevant comorbidities to support the request. Clinical consult notes may be included to support intolerances and contraindications to earlier treatment lines.
2. Ripretinib should not be used in patients with active central nervous system metastases.

Renewal criteria:

Renewal of reimbursement of ripretinib will be considered for patients who demonstrate a response to therapy and have not experienced unacceptable toxicity.

Approved Dose: 150 mg daily with dose adjustments as necessary based on the product monograph.

Approval duration for initials and renewals: 6 months

EAP Drug Request Form:

Standard Form for EAP Drug Requests